Characterization of extracellular vesicles isolated from different liquid biopsies of uveal melanoma patients

Carmen Luz Pessuti1, Deise Fialho Costa1,2, Kleber S. Ribeiro1,3, Mohamed Abdouh1, Thupten Tsering2, Heloisa Nascimento1, Alessandra G. Commodaro1, Allexya Affonso Antunes Marcos1, Ana Claudia Torrecilhas1, Rubens N. Belfort1, Rubens Belfort Jr1, Julia Valdemarin Burnier2,4,5

1Department of Ophthalmology, Federal University of São Paulo, Vision Institute, IPEPO, São Paulo - Brazil
2Cancer Research Program, McGill University Health Centre Research Institute, Montreal, Quebec - Canada
3Department of Pharmaceutical Sciences, Federal University of São Paulo, Diadema, São Paulo - Brazil
4Department of Oncology, McGill University, Montreal, Quebec - Canada
5Experimental Pathology Unit, Department of Pathology, McGill University, Montreal, Quebec - Canada

ABSTRACT

Purpose: Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Extracellular vesicles (EVs) have been extensively studied as a biomarker to monitor disease in patients. The study of new biomarkers in melanoma patients could prevent metastasis by earlier diagnosis. In this study, we determined the proteomic profile of EVs isolated from aqueous humor (AH), vitreous humor (VH), and plasma from UM patients in comparison with cancer-free control patients.

Methods: AH, VH and plasma were collected from seven patients with UM after enucleation; AH and plasma were collected from seven cancer-free patients with cataract (CAT; control group). EVs were isolated using the membrane-based affinity binding column method. Nanoparticle tracking analysis (NTA) was performed to determine the size and concentration of EVs. EV markers, CD63 and TSG101, were assessed by immunoblotting, and the EV proteome was characterized by mass spectrometry.

Results: Mean EV concentration was higher in all analytes of UM patients compared to those in the CAT group. In the UM cohort, the mean concentration of EVs was significantly lower in AH and plasma than in VH. In contrast, the mean size and size distribution of EVs was invariably identical in all analyzed analytes and in both studied groups (UM vs. CAT). Mass spectrometry analyses from the different analytes from UM patients showed the presence of EV markers.

Conclusion: EVs isolated from AH, VH, and plasma from patients with UM showed consistent profiles and support the use of blood to monitor UM patients as a noninvasive liquid biopsy.

Keywords: Aqueous humor, Extracellular vesicles, Liquid biopsy, Plasma, Proteomic analysis, Uveal melanoma, Vitreous humor

Introduction

Uveal melanoma (UM) is a primary intraocular tumor in adults that accounts for less than 5% of all melanoma cases (1,2). The incidence of UM has remained stable at ~5.1 per million since the 1970s with subtle differences depending on geographic location, as well as environmental and occupational factors (1). Despite excellent control of local disease, prognosis remains poor due to metastatic progression affecting ~50% of patients (2-4). Mortality rates for UM are unchanged over the past decades (1).

Extracellular vesicles (EVs) have emerged as biomarkers in various cancers and provide valuable clinical information (5,6). Their use as a biomarker assay has gained interest as a new tool for monitoring of cancer patients; however, standardization and validation of EVs as a biomarker are needed (4,7).

EVs are small lipid bilayer particles released from all types of cells and found in different body fluids, most commonly the blood, but have also been detected in aqueous humor (AH) (8,9). EVs are classified mainly into exosomes (50-100 nm), microvesicles (100-1000 nm), and apoptotic bodies (50 nm-2 μm) based on their biogenesis, number, size, distinct biological functions and markers (10-16). Exosomes are a constitutive and abundant component of the vitreous (17).

EVs are involved in the transfer of biological macromolecules to recipient cells, and modulating various physiological
and pathological processes, such as pathogen dissemination and regulation of the host immune system (18-20). Recent studies have shown that tumor cells release large amounts of EVs that can be uptaken by malignant and stromal cells, inducing tumor progression (21,22). They have been shown to play a major role in mediating metastasis, ranging from oncogenic reprogramming of malignant cells to the formation of pre-metastatic niches (23-25). Furthermore, our group and others have shown that cancer-derived exosomes can transfer bioactive molecules such as proteins, DNA, mRNAs, and miRNAs to recipient cells, thereby changing their function (26-29).

In ocular and cutaneous melanoma, the concentration of EVs and proteins is increased in patients compared to healthy individuals and has been shown to correlate with disease progression (30,31). Moreover, the profile of circulating EV-derived miRNAs is often altered in human cancers, and EVs from UM patients have been shown to contain miR-146, a potential circulating marker in UM (32). Recently, we have reported that the number of EVs produced and the profile of tumor-associated proteins vary between normal melanocytes and UM cell lines, and also between primary and metastatic UM cell lines (33). EVs released by metastatic melanoma cells were enriched in proteins (9,10,23) involved in the pre-metastatic niche formation (25), suggesting their role in preparing the environment for colonization by circulating tumor cells (CTCs).

There is a lack of detailed characterization of EVs in this disease as well as in nonblood-based liquid biopsy. In this study, our aim was to determine the proteomic profile of EVs isolated from AH, vitreous humor (VH), and plasma from patients with UM and to compare with cancer-free control patients.

**Materials and methods**

**Patients**

A total of 14 participants were enrolled for this study: 7 patients diagnosed with primary UM, and 7 healthy controls undergoing cataract surgery at the Department of Ophthalmology, Federal University of São Paulo (UNIFESP/EPM), Brazil. The patients were recruited from July 2019 to December 2019 at the Department of Ophthalmology of the UNIFESP/EPM. The clinical characteristics of the study population are described in Table I.

This study was approved by the ethics committee investigational review board (CEP number 2198149) and adhered to the principles of the Declaration of Helsinki and Resolution 196/96 of the Ministry of Health, Brazil. Informed consent was obtained from all participants.

**Sample collection**

AH and plasma samples were collected from UM patients and controls. Additionally, VH samples were collected from UM patients. Peripheral blood (10 mL) was collected in ethylenediaminetetraacetic acid (EDTA) tubes. The tubes were centrifuged for 10 minutes at 1,900 × g, and plasma were collected. VH and AH samples from UM patients were collected from the enucleated eyes after the surgery with a syringe and fine needle. In the control group, AH samples were collected during cataract surgery. All routine surgical procedures were followed. All collected samples were kept at −80°C until the experimental procedure.

**TABLE I - Clinical features of patients enrolled in this study**

| Patients | Sex | Age (years) | Cell Types | Size | TNM |
|----------|-----|-------------|------------|------|-----|
| CAT1     | Male| 70          | N/A        | N/A  | N/A |
| CAT2     | Female| 77         | N/A        | N/A  | N/A |
| CAT3     | Female| 82         | N/A        | N/A  | N/A |
| CAT4     | Female| 77         | N/A        | N/A  | N/A |
| CAT5     | Female| 75         | N/A        | N/A  | N/A |
| CAT6     | Male| 76          | N/A        | N/A  | N/A |
| CAT7     | Female| 63         | N/A        | N/A  | N/A |
| UM1      | Male| 72          | Mixed UM, predominance of spindle cells affecting the ciliary body and choroid | 1.9 × 0.6 | pT4E |
| UM2      | Female| 86         | Epithelioid choroidal melanoma | 1.2 × 1.1 | pT3B |
| UM3      | Female| 53         | Mixed choroidal melanoma, predominance of spindle cells | 1.3 × 1.0 | pT3A |
| UM5      | Male| 63          | Mixed UM, predominance of spindle cells infiltrating the choroid and ciliary body | 1.2 × 1.5 | pT3B |
| UM6      | Female| 61         | Mixed UM, predominance of epithelioid cells | 1.0 × 0.8 | pT2 |
| UM8      | Female| 65         | Mixed UM, predominance of spindle cells infiltrating the choroid and ciliary body | 2.8 × 0.7 | pT4B |
| UM9      | Female| 39         | Mixed choroidal melanoma, predominance of epithelioid cells | 1.5 × 1.2 | pT3A |

Size refers to tumor size (base diameter × thickness [cm × cm]).

CAT = cataract, control group; N/A = not applicable; TNM = tumor, node, metastasis; UM = uveal melanoma.
**EV purification and characterization**

The protocol for EV isolation was performed according to the guidelines of the International Society for Extracellular Vesicles (ISEV) (10). Samples were centrifuged at 16,000 × g for 10 minutes at 4°C to eliminate cellular debris. Then, EV isolation was performed using the exoEasy Maxi Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions (10,11,34-36). Isolated EVs were diluted 100 × in phosphate-buffered saline (PBS) and analyzed by nanoparticle tracking analysis (NTA) using the NanoSight NS300 instrument (Malvern Analytical, UK). PBS was used as a diluent. Samples and diluent were read in triplicates for 30 seconds at 20 frames per second. The NTA 3.2 software was used to estimate the concentration and size of the particles.

**Immunoblotting**

EVs isolated from patients and controls were lysed in RIPA buffer containing complete mini protease inhibitors (Sigma) at 4°C for 30 minutes. Samples were sonicated for 2 seconds (three times), and spun at 13,000 × g for 30 minutes at 4°C. Protein concentrations were quantified by the BCA assay (Thermo Fisher Scientific). Protein samples were processed for immunoblotting and mass spectrometry (MS).

EV-derived proteins (20 µg) were separated using 12% MiniPROTEAN® precast polyacrylamide gel (Bio-Rad). Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad). Membranes were blocked for 1 hour at room temperature with 5% nonfat dry milk in 1X Tris-buffer saline with 0.05% Tween 20 (TBST). Membranes were probed with anti-TSG101 (Abcam; 1:1,000) and anti-C6D3 (Abcam; 1:1,000), anti-Alix (ThermoFisher Scientific 1:1,000), anti-β-actin (Sigma 1:1,000), anti-tenascin C (abcam 1:1,000), anti-vimentin (abcam 1:500) primary antibodies, followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Sigma 1:1,000), anti-tenascin (Sigma 1:1,000) and goat anti-mouse (Sigma 1:3,000) secondary antibodies. Membranes were washed five times for 10 minutes each time after each incubation and developed using ECL prime Western blot detection (GE Healthcare). Protein signals were visualized using the ChemiDoc XRS + System.

**MS analysis**

MS analysis was performed in nine samples [AH (n = 3), plasma (n = 3), and VH (n = 3)] from UM-5, UM-6, and UM-8 patients; 20 µg of EV proteins from each sample was loaded onto a single stacking gel band to remove contaminants such as lipids, detergents, and salts. Each sample was run in duplicate.

The gel band was reduced with DTT (dithiothreitol), alkylated with iodoacetic acid, and digested with trypsin. Extracted peptides were resolubilized in 0.1% aqueous formic acid and loaded onto a Thermo Scientific Acclaim PepMap (75 µm inner diameter × 2 cm, C18 3 µm particle size) precolumn and then onto an Acclaim PepMap EASY-Spray (75 µm inner diameter × 15 cm with 2 µm C18, 2 µm beads) analytical column separation using a Dionex UltiMate 3000 uHPLC at 250 nL/min with a gradient of 2-35% organic (0.1% formic acid in acetonitrile) over 3 hours. Peptides were analyzed using a Thermo Orbitrap Fusion MS operating at 120,000 resolution (full width at half maximum in MS1) with Higher energy Collisional Dissociation (HCD) sequencing (15,000 resolution) at top speed for all peptides with a charge of Z+ or greater. The MS raw data were converted into *.mgf format (Mascot generic format) for searching using the Mascot 2.6.2 search engine (Matrix Science) against human protein sequences (Uniprot 2019). The database search results were loaded onto Scaffold Q+ Scaffold_4.10.0 (Proteome Sciences) for spectral counting, statistical treatment, data visualization, and quantification. Protein threshold >99%, peptide threshold >95%, and two of a minimum number of unique peptides were applied in Scaffold Q+ to increase the confidence level of identified proteins. Additional filters such as p-value cut-off of 0.05 and a fold-change change of ≥2 were used to identify the differential expression of proteins. The identified protein list in Scaffold was exported to Microsoft Excel and uploaded into the DAVID Bioinformatics database (version 6.8) for gene ontology (GO) analyses (i.e., biological process, cellular component, and KEGG pathway). In addition, bioinformatic analysis and Vesiclepedia database (37) search were performed using the FunRich software (version 3.1.3) (37-39).

**Statistical analysis**

Statistical analysis was performed using the GraphPad software (Pism, version 5.00 for Windows; GraphPad, San Diego, CA). The Mann-Whitney test was used to determine the statistical difference between respective groups. The results are expressed as mean ± standard deviation (SD). A p-value < 0.05 was considered significant.

**Results**

**Characterization and isolation of EVs from plasma, AH, and VH**

EVs were isolated from the plasma, AH, and VH of UM patients, and AH and plasma of cataract patients. Immunoblotting analysis showed the expression of EV markers CD63, TSG101, and Alix with different expression levels depending on the analyzed samples (Fig. 1A, B, and Supplementary Figure A). The expression of CD63 and Alix was higher in UM EVs than in CAT EVs (Fig. 1A, and Supplementary Figure A). Moreover, the expression of both CD63 and TSG101 was higher in EVs isolated from VH and plasma than in EVs isolated from AH (Fig. 1A, B). NTA from all samples showed that EVs ranged from 80 to 442 nm in size, with similar 10 percentile mean (D10) size (133 nm, 135 nm, and 139 nm) in plasma, AH, and VH, respectively (Fig. 1C, D). When analyzing sizes of isolated UM EVs, no difference was observed in all samples: 219 ± 26 nm (range: 168-241) in plasma, 211 ± 37 nm (range: 173-265) in AH and 216 ± 71 nm (range: 110-314) in VH (Fig. 1D). Also, no difference was observed in the average size of EVs from AH and plasma between the UM and CAT groups (Fig. 1D).

In the UM cohort, the concentration of EVs ranged from 2.6 × 10^10 to 9 × 10^10 particles/mL in AH, VH, and plasma samples (Fig. 1E). The mean concentration of EVs in VH (6.6 × 10^10 particles/mL) was significantly higher when compared to AH.
(10^{10} \text{ particles/mL, } p < 0.01) and plasma (2.7 \times 10^{10} \text{ particles/mL, } p < 0.01) (Fig. 1E). No difference was observed in the concentration of AH-derived EVs between the UM and CAT groups. In contrast, the concentration of plasma-derived EVs was significantly higher in UM patients than in the CAT control group (p < 0.001) (Figs. 1F, G). Notably, we did not find any correlation between the concentrations of EVs isolated from UM patients and ocular tumor size (Fig. 1H, I).

**EV protein cargo from plasma AH and VH**

To gain an in-depth understanding of the protein cargo in EVs isolated from the different analytes, we performed whole proteomic analysis by MS. For this purpose, we focused our analysis on EVs isolated from three UM patients (UM-5, UM-6, and UM-8). Our goal from this analysis was to determine whether these EVs carried common protein cargo and
also the nature of those proteins. We identified 542 proteins of which 498 (92%) overlap with EV proteins previously reported in the Vesiclepedia database (Supplementary Table A, List of EV-contained proteins identified by MS screening) (Fig. 2A) (37). As a readout for the purity of isolated EVs, we detected proteins that are specific to the tissue of origin (i.e., complement and coagulation factors in EVs from the plasma, melanocyte protein PMEL and HTRA1 in the VH, and beta- and gamma-crystallin in the AH) (Tab. II). In addition, protein cargo detected in isolated EVs included typical EV protein signatures such as ESCRT components CD81, CD63, CD9, HLA, annexins and syntenin (Supplementary Table A, List of EV-contained proteins identified by MS screening). Moreover, herein, we report the presence of 44 novel proteins not previously reported in the Vesiclepedia database (37); 2 are present in all EVs, 4 are present in EVs from plasma and VH, 4 are present in EVs from VH and AH, and the rest are unique to EVs from a single analyte (Tab. III).

Interestingly, 209 (39%) of the identified proteins were shared between EVs from the three assays (Fig. 2B). In addition, when we analyzed each analyte separately, we observed that EVs from the three samples shared 106 (33%) proteins in AH, 181 (44%) in VH, and 247 (73%) in plasma (Fig. 2C-E).

Proteins by GO analysis in specific biological processes

Of the proteins found in our proteomic analyses data from UM patients, 344 proteins were detected from plasma EVs, 334 in EVs from AH, and 421 in EVs from VH (Fig. 2B). To identify the physiological processes to which these proteins were associated, clustering was conducted into GO categories using the DAVID bioinformatics platform (Fig. 3). Characterization by biological process highlighted categories related to retina homeostasis, regulation of apoptosis, cell growth, and the activation of pathways involved in cancer cell biology (i.e., MAPK/ERK cascades). In addition, of the highly expressed proteins, several clustered in the categories of cell-cell adhesion and movement of cell or subcellular component (Fig. 3A). When clustering the proteins based on cellular component, we found they grouped into EV categories (i.e., vesicles) (Fig. 3B). Molecular functions clustering using KEGG pathway analysis revealed that isolated EVs were enriched for proteins related to immune escape from cancer, such as those involved in complement and coagulation cascades, and proteins involved in cell metabolic activities and interaction with extracellular matrix (ECM). Particularly, a panel of proteins clustered in the PI3k-Akt signaling pathway and the proteoglycan group were exclusively present in plasma-isolated EVs (Fig. 3C).
UM arises from melanocytes of the uveal tract (25,34). EVs isolated from the AH and VH may contain proteins reflective of UM cells. We pooled our data from intraocular-derived EVs by focusing on proteins that regulate tumor growth and oncogenesis (Tab. IV). This identified a panel of proteins that are mainly involved in protecting cells against apoptosis, controlling cell growth, promoting angiogenesis, and inducing cell spreading (i.e., clusterin, alpha-enolase, fibulin-1, cathepsin, HSP, ECM1, MET, and GAS6). Moreover, vimentin (an intermediate filament protein that is overexpressed in epithelial tumors such as UM) was detected in VH-derived EVs (Tab. IV) (36,38-40).

Plasma-isolated EVs were also enriched in proteins involved in the regulation of cell proliferation (i.e., SPARC, tenasin, plexin) and cell survival (i.e., clusterin), and the metastatic process such as metastatic niche organization (i.e., ECM1, ECM2, emilin, C-reactive protein [CRP], oncoprotein-induced transcript 3 [OIT3], and integrins) (Tab. V, and

---

**Table II - Protein readout for the purity of isolated EVs**

| Identified Proteins | Spectrum Count | AH | VH | P |
|---------------------|---------------|----|----|---|
| **Plasma**          |               |    |    |   |
| Coagulation factor V| FAS           | 2  | 0  | 146|
| C4b-binding protein alpha chain | C4BPA | 1 | 7 | 127 |
| Coagulation factor IX | FA9 | 1 | 16 | 79 |
| von Willebrand factor | VWF | 0 | 0 | 72 |
| Coagulation factor X | FA10 | 2 | 11 | 70 |
| Multimerin-1 | MMRN1 | 0 | 0 | 33 |
| Platelet glycoprotein Ib alpha chain | GP1BA | 0 | 2 | 22 |
| C4b-binding protein beta chain | C4BPB | 0 | 0 | 14 |
| Serum amyloid P-component | SAMP | 0 | 7 | 14 |
| C-reactive protein | CRP | 1 | 1 | 13 |
| Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 | SVEP1 | 0 | 0 | 2 |
| Serum amyloid A-1 protein | SAA1 | 0 | 0 | 1 |
| **VH**              |               |    |    |   |
| Pigment epithelium-derived factor | PEDF | 37 | 111 | 13 |
| Retinol-binding protein 3 | RET3 | 3 | 111 | 0 |
| Melanocyte protein PMEL | PMEL | 0 | 27 | 1 |
| Serine protease HTRA1 | HTRA1 | 0 | 8 | 0 |
| Retinaldehyde-binding protein 1 | RLBP1 | 0 | 2 | 0 |
| Retinoschisin | XLSR1 | 0 | 2 | 0 |
| Interphotoreceptor matrix proteoglycan 1 | IMPG1 | 0 | 1 | 0 |
| **AH and VH**       |               |    |    |   |
| Opticin             | OPT           | 12 | 12 | 0  |
| **AH**              |               |    |    |   |
| Beta-crystallin B1 | CRBB1 | 179 | 2 | 1 |
| Alpha-crystallin A2 chain | CRYA2 | 146 | 0 | 0 |
| Alpha-crystallin B chain | CRYAB | 139 | 7 | 0 |
| Gamma-crystallin S | CRYGS | 97 | 1 | 0 |
| Beta-crystallin A3 | CRBA1 | 76 | 0 | 0 |
| Beta-crystallin A4 | CRBA4 | 52 | 0 | 0 |
| Gamma-crystallin C | CRGC | 44 | 0 | 0 |
| Gamma-crystallin D | CRGD | 42 | 0 | 0 |
| Retinal dehydrogenase 1 | AL1A1 | 41 | 0 | 0 |
| Filensin            | BFSP1 | 2 | 0 | 0 |
| Phakinin            | BFSP2 | 2 | 0 | 0 |

Data are derived from three patients (UM-5, UM-6, and UM-8) and samples were run in duplicates.
AH = aqueous humor; EV = extracellular vesicle; ID = alternative name; P = plasma; VH = vitreous humor.
### TABLE III - Newly characterized protein from EVs isolated from plasma, aqueous humor, or vitreous humor

| Identified Proteins                                                                 | ID       | P  | VH | AH |
|-------------------------------------------------------------------------------------|----------|----|----|----|
| Complement C4-B                                                                      | CO4B     | Y  | Y  | Y  |
| Beta-crystallin B1                                                                   | CRBB1    | Y  | Y  | Y  |
| Vitamin K-dependent protein C                                                        | PROC     | Y  | Y  | N  |
| Immunoglobulin J chain                                                               | IGJ      | Y  | Y  | N  |
| L-selectin                                                                          | LYAM1    | Y  | Y  | N  |
| Neurillin-2                                                                         | NRP2     | Y  | Y  | N  |
| Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D            | SRCRL    | Y  | N  | N  |
| Extracellular matrix protein 2                                                       | ECM2     | Y  | N  | N  |
| Plexin domain-containing protein 1                                                  | PLDX1    | Y  | N  | N  |
| Retinol-binding protein 3                                                            | RET3     | N  | Y  | Y  |
| Opticin                                                                             | OPT      | Y  | N  | Y  |
| Beta-1,4-glucuronyltransferase 1                                                    | B4GA1    | Y  | Y  | Y  |
| Wnt inhibitory factor 1                                                              | WIFI1    | N  | Y  | Y  |
| Beta-Ala-His dipeptidase                                                             | CNDP1    | N  | Y  | N  |
| Receptor-type tyrosine-protein phosphatase zeta                                      | PTPRZ    | N  | Y  | N  |
| Macrophage colony-stimulating factor 1 receptor                                      | CSF1R    | N  | Y  | N  |
| Serpin E3                                                                           | SERP3    | N  | Y  | N  |
| Cadherin-related family member 1                                                    | CDHR1    | N  | Y  | N  |
| Clusterin-like protein 1                                                             | CLUL1    | N  | Y  | N  |
| Retinaldehyde-binding protein 1                                                      | RLBPI    | N  | Y  | N  |
| Retinoschisin                                                                       | XLSR1    | N  | Y  | N  |
| Adipocyte plasma membrane-associated protein                                         | APMAP    | N  | Y  | N  |
| Left-right determination factor 2                                                    | LFTY2    | N  | Y  | N  |
| Neuronal cell adhesion molecule                                                      | NRCAM    | N  | Y  | N  |
| Interphotoreceptor matrix proteoglycan 1                                             | IMPG1    | N  | Y  | N  |
| Triggering receptor expressed on myeloid cells 2                                     | TREM2    | N  | Y  | N  |
| Cathepsin L1                                                                        | CATL1    | N  | Y  | N  |
| Endothelial lipase                                                                  | LIPE     | N  | Y  | N  |
| BPI fold-containing family B member 4                                                | BPIB4    | N  | Y  | N  |
| Semaphorin-3B                                                                       | SEM3B    | N  | Y  | N  |
| Zinc transporter ZIP12                                                               | S39AC    | N  | Y  | N  |
| Tskushin                                                                            | TSK      | N  | Y  | N  |
| Beta-crystallin A3                                                                  | CRBA1    | N  | N  | Y  |
| Beta-crystallin A4                                                                  | CRBA4    | N  | N  | Y  |
| Gamma-crystallin C                                                                  | CRGC     | N  | N  | Y  |
| Gamma-crystallin D                                                                  | CRGD     | N  | N  | Y  |
| Gamma-crystallin B                                                                  | CRGB     | N  | N  | Y  |
| Beta-crystallin B3                                                                  | CRBB3    | N  | N  | Y  |
| Filensin                                                                            | BFSP1    | N  | N  | Y  |
| Protein S100-B                                                                      | S100B    | N  | N  | Y  |
| Secreted frizzled-related protein 3                                                 | SFRP3    | N  | N  | Y  |
| Phakinin                                                                            | BFSP2    | N  | N  | Y  |
| DNA polymerase theta                                                                | DPOLQ    | N  | N  | Y  |
| Protein kinase C-binding protein NELL2                                               | NELL2    | N  | N  | Y  |

Data are derived from three patients (UM-5, UM-6, and UM-8) and samples were run in duplicates.

AH = aqueous humor; ID = alternative name; N = absent; P = plasma; VH = vitreous humor; Y = present.
Fig. 3 - Gene ontology classification of EV protein cargo. The most enriched categories in biological process (A), cellular component (B), and molecular function (C) are shown. Data were collected from three UM patient analytes repeated twice (UM5-1, UM5-2, UM6-1, UM6-2, UM8-1, and UM8-2). EV = extracellular vesicle; UM = uveal melanoma.
Supplementary Figure A) (41-44). These data suggest that, while AH- and VH-isolated proteins govern in situ UM growth and motility, those contained in the plasma-derived EVs are more involved in UM cell metastatic organotropism and the maintenance of the metastatic niche.

Discussion

EVs have been reported to regulate many aspects of physiological and pathological processes such as cancer. They carry substances that mirror the content of their cell of origin and have the capability to exhibit different biological functions on recipient cells via trafficking of different factors, that is, nucleic acids, proteins, lipids (10,21,44-52). EVs released from tumor cells promote cell proliferation, migration, invasion, angiogenesis, and metastases (54,57-63). EV cargo could be used as circulating biomarkers in liquid biopsy, mainly in the context of cancer. In the present study, we determined the proteomic profile of EVs isolated from AH, VH, and plasma from patients with UM in comparison with cancer-free control patients.
The size and distribution of EVs detected in the three samples were consistent with exosomes (10). In the blood samples, a significantly higher concentration of EVs was found in UM patients compared to the control group. This is in agreement with our recent observations that UM cell lines shed more EVs than normal choroidal melanocytes (33). Another study suggests that EV has potential roles in cancer progression and invasion (11). Interestingly, the mean concentration of EVs in VH from UM patients was higher when compared to plasma and AH, which seems normal as UM takes place in the posterior segment of the eye.

We showed that EVs derived from AH, VH, and plasma were positive for CD63 and TSG101 markers. Besides, the expression of CD63 was higher in UM EVs in comparison with EVs isolated from samples of control group. Our data corroborate with a study that demonstrated high levels of CD63 in exosomes isolated from plasma of melanoma patients (53). Also a study showed exosomal marker TSG101 was detected in plasma-derived exosome from ovarian cancer patients (21).

We observed that the plasma EV proteomic cargo resembles that of EVs obtained from AH and VH. Although we found that only 209 proteins (39%) were shared between EVs from the three samples (a value that reached 221 proteins (49%) and 279 proteins (57%) when taking into account only AH vs. plasma and VH vs. plasma, respectively), this is not surprising as the plasma is the common carrier of EVs from different tissues.

Moreover, proteomic mining of isolated EVs from UM group identified a set of proteins involved in oncogenesis (i.e., regulation of cell proliferation and survival, promotion of angiogenesis, and cell invasion) and metastasis (i.e., cell spreading and metastatic niche organization) (36,38-43,54). For example, SPARC abrogation has been reported to reduce cell proliferation in UM (41). Cathepsin, a lysosomal acid proteinase, was reported to be involved in different cancer types, especially in regulating UM invasion potential (36,40). Galectin has been shown to facilitate cell migration, to promote metastasis, and to be a hallmark for cancer aggressiveness (55,56). OIT3 is involved in the development and function of the liver, which is the primary site for UM metastasis (54). In addition, several integrins were detected in the isolated EVs from the UM group. These proteins are involved in adhesion to extracellular matrix components and specific organotropism of metastasizing cancer cells (43,64). The integrins present in the EV preparations demonstrate an upregulation of various signal transduction molecules such as S100-A. It has been shown that exosome-derived integrins are internalized by target cells and activate SRC phosphorylation and proinflammatory S100 gene expression (64). Furthermore, EVs from melanoma were found to upregulate S100 proteins in recipient target cells, resulting in vascular leakiness and promotion of metastasis (31,65).

Other proteins found in the datasets such as heat shock proteins and CRP are indicators of worse prognosis in UM (38,42). In addition, melanocyte-specific type I transmembrane glycoprotein (PMEL) was enriched in EVs from VH and less in EVs from plasma. This protein is released by proteolytic ectodomain shedding and may be used as a melanoma-specific blood marker (5,6,67,68).

Interestingly, the recovered protein cargo contained factors involved in cell proliferation, cell survival, oncogenesis, cell invasion, and metastatic niche organization. Together, these data suggest that plasma from UM patients could be used as liquid biopsy platform for patient diagnosis and non-invasive monitoring.

Using clustering analysis based on GO biological process, categories consistent with retinal homeostasis and activation of intracellular pathways involved in cancer cell biology were identified (i.e., MAPK/ERK cascades). Almost all UM are characterized by mutations in one of GNAQ, GNA11, PLCB4, or CYSLT2 genes, and these are upstream activators of the MAPK/ERK cascade (66).

One limitation of this study is the low number of analyzed samples for the proteomic characterization (three UM samples). However, the consistency of the data between the analyzed samples makes the conclusions valuable. Unfortunately, due to the lack of material, performing differential protein expression analysis is not possible at this stage. Studies including more samples are in progress to address this weakness.

Liquid biopsy is already distinguishing cancer-free individuals from non-small cell lung cancer patients and pancreatic ductal adenocarcinoma by the quantitative analysis of exosomal miR-21 and miR-10b, respectively (67). Intra-EV metabolites from prostate cancer patients before and after prostatectomy revealed novel biomarkers (68). One must remember that not only tumor cells release exosomal RNA to affect biological functions but also many normal cells will secrete the same exosomal RNA physiologically (69). As mentioned before, exosomal integrins could be used to predict organ-specific metastasis (64). Therefore, therapy supported by liquid biopsy could be driven in a premature way in case of early metastasis diagnosis or even somehow by targeting and blocking cancer pre-metastatic EV development. Certainly, this promising new tool has to be used with caution, and further studies are needed.

In conclusion, it has been observed that VH is significantly enriched in EVs when compared to AH and plasma in UM patients. EV concentrations in plasma and AH from UM patients was higher when compared to those in the cataract group. Proteomic analysis demonstrated that EVs from the different samples shared a panel of proteins, suggesting that circulating UM EVs mirrored the in situ shed of EVs (i.e., AH and VH). EVs isolated from AH, VH, and plasma from patients with UM showed consistent profiles and support the use of blood to monitor UM patients as a noninvasive liquid biopsy.

Acknowledgments

The authors would like to acknowledge the technical expertise and scientific support of the Proteomics facility of the MUHC-RI, especially Lorne Taylor and Amy Wong.

Disclosures

Financial support: This work was supported by CNPq process No. 429571/2018-6, FAPESP, and CAPES. RBJ is an investigator for CNPq Brazil.

Conflict of interest: The authors report no conflict of interest.

Data Availability: All data generated and analyzed during this study are included in this manuscript.
38. Faingold D, Marshall JC, Antecka E, et al. Immune expression and inhibition of heat shock protein 90 in uveal melanoma. Clin Cancer Res. 2008;14(3):847-855. CrossRef PubMed

39. Wu X, Zhou J, Rogers AM, et al. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012;22(2):123-132. CrossRef PubMed

40. Pardo M, García A, Antrobus R, Blanco MJ, Dwek RA, Zitzmann N. Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J Proteome Res. 2007;6(7):2802-2811. CrossRef PubMed

41. Maloney SC, Marshall JC, Antecka E, et al. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation. Anticancer Res. 2009;29(8):3059-3064. PubMed

42. Schicher N, Edelhauser G, Harmankaya K, et al. Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma—a single centre experience. J Eur Acad Dermatol Venereol. 2013;27(3):e394-e399. CrossRef PubMed

43. Janik ME, Lityńska A, Przybyło M. Studies on primary uveal and cutaneous melanoma cell interaction with vitronectin. Cell Biol Int. 2014;38(8):942-952. CrossRef PubMed

44. Lykke-Andersen S, Brodersen DE, Jensen TH. Origins and activities of the eukaryotic exosome. J Cell Sci. 2009;122(Pt 10):1487-1494. CrossRef PubMed

45. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20(9):1487-1495. CrossRef PubMed

46. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 2012;40(21):10937-10949. CrossRef PubMed

47. Di Vizio D, Morello M, Dudley AC, et al. Large oncosomes. Nat Rev Mol Cell Biol. 2013;16(11):1573-1584. CrossRef PubMed

48. Kahler C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869-3875. CrossRef PubMed

49. Théry C, Boussac M, Véron P, et al. Proteomic and transcriptomic analysis of extracellular vesicles secreted to the extracellular compartment of MDA-MB-231, a breast cancer cell line. J Proteomics. 2012;75(7):1927-1935. CrossRef PubMed

50. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228. CrossRef PubMed

51. Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular vesicles: composition, biological relevance, and methods of study. Bioessays. 2015;35(5):783-797. CrossRef PubMed

52. Inamdar S, Nitiyanandan R, Rege K. Emerging applications of exosomes in cancer therapeutics and diagnostics. Bioeng Transl Med. 2017;2(1):70-80. CrossRef PubMed

53. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4(4):e5219. CrossRef PubMed

54. Xu ZG, Du JJ, Zhang X, et al. A novel liver-specific zona pelucida domain containing protein that is expressed rarely in hepatocellular carcinoma. Hepatology. 2003;38(3):735-744. CrossRef PubMed

55. Sindrewicz P, Lian LY, Yu LG. Interaction of the oncocytic Thomsen-Friedenreich antigen with galectins in cancer progression and metastasis. Front Oncol. 2016;6:79. CrossRef PubMed

56. Ahmed H, AlSadek DM. Galectin-3 as a potential target to prevent cancer metastasis. Clin Med Insights Oncol. 2015;9:113-121. CrossRef PubMed

57. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10(5):619-624. CrossRef PubMed

58. Aga M, Bentz GL, Raffa S, et al. Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene. 2014;33(37):4613-4622. CrossRef PubMed

59. Abboud M, Hamam D, Gao ZH, Arena V, Arena M, Arena GO. Exosomes isolated from cancer patients’ sera transfer malignant traits and confer the same phenotype of primary tumors to oncosuppressor-mutated cells. J Exp Clin Cancer Res. 2017;36(1):113. CrossRef PubMed

60. Xu J, Liao K, Zhou W. Exosomes regulate the transformation of cancer cells in cancer stem cell homeostasis. Stem Cells Int. 2018;2018:4837370. CrossRef PubMed

61. Shen M, Ren X. New insights into the biological impacts of immune cell-derived exosomes within the tumor environment. Cancer Lett. 2018;431:115-122. CrossRef PubMed

62. Dos Anjos Pultz B, Andrés Cordero da Luz F, Socorro Faria S, et al. The multifaceted role of extracellular vesicles in metastasis: priming the soil for seeding. Int J Cancer. 2017;140(11):2397-2407. CrossRef PubMed

63. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836-848. CrossRef PubMed

64. Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(758):329-335. CrossRef PubMed

65. Che P, Yang Y, Han X, et al. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Sci Rep. 2015;5(1):8453. CrossRef PubMed

66. Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109-140. CrossRef PubMed

67. Li S, Yi M, Dong B, Tan X, Luo S, Wu K. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer. 2021;148(11):2640-2651. CrossRef PubMed

68. Puhka M, Takahiro M, Nordberg ME, et al. Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 2017;7(16):3824-3841. CrossRef PubMed

69. Vafaei S, Fattahi F, Ebrahimi M, Janani L, Shariftabrizi A, Madjd Z. Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review. Cancer Manag Res. 2019;11:8669-8698. CrossRef PubMed